These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. Jones EW; Cockbill SR; Cowley AJ; Hanley SP; Heptinstall S Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):39S-44S. PubMed ID: 6401999 [TBL] [Abstract][Full Text] [Related]
31. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. Defreyn G; Machin SJ; Carreras LO; Dauden MV; Chamone DA; Vermylen J Br J Haematol; 1981 Sep; 49(1):29-41. PubMed ID: 6268139 [TBL] [Abstract][Full Text] [Related]
32. Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. Vermylen J; Deckmyn H Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):17S-22S. PubMed ID: 6297527 [TBL] [Abstract][Full Text] [Related]
33. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Sills T; Heptinstall S Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954 [TBL] [Abstract][Full Text] [Related]
34. The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals. Cowley AJ; Jones EW; Carter AJ; Hanley SP; Heptinstall S Br J Clin Pharmacol; 1985 Jan; 19(1):1-8. PubMed ID: 2983748 [TBL] [Abstract][Full Text] [Related]
36. Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha. Faili A; Randon J; Vargaftig BB; Hatmi M Biochem Pharmacol; 1993 May; 45(9):1815-20. PubMed ID: 8388209 [TBL] [Abstract][Full Text] [Related]
37. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade. Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187 [TBL] [Abstract][Full Text] [Related]
38. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278 [TBL] [Abstract][Full Text] [Related]
39. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320 [TBL] [Abstract][Full Text] [Related]
40. Competitive antagonism at thromboxane receptors in human platelets. Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]